关键词: 肝内胆管癌, 转化治疗, 化疗, 免疫治疗

Abstract: This paper presents a case of a 43-year-old male diagnosed with left lobe intrahepatic cholangiocarcinoma following the detection of a left hepatic mass during a routine physical examination. Imaging evaluations confirmed tumor invasion into the middle hepatic vein, inferior vena cava, and hilar lymph nodes, leading to an initial assessment of unresectable disease. Following a multidisciplinary team （MDT） discussion, the patient was initiated on neoadjuvant therapy consisting of Gemcitabine/Cisplatin/Albumin-bound paclitaxel chemotherapy combined with sintilimab immunotherapy. Following four cycles of conversion therapy, the tumor significantly shrank, and the tumor marker CA19-9 markedly decreased, creating an opportunity for curative surgery.Subsequently, the patient successfully underwent extended left hepatectomy, caudate lobectomy,and regional lymph node dissection. Postoperative pathological examination confirmed an R0 resection. The patient recovered well postoperatively and continued adjuvant therapy. Over a follow-up period exceeding 24 months, no evidence of tumor recurrence was identified, and the patient maintained a favorable quality of life. This case suggests that chemotherapy combined with immunotherapy as a neoadjuvant approach can effectively convert initially unresectable locally advanced intrahepatic cholangiocarcinoma, providing patients with an opportunity for curative surgery and survival benefits.

Key words: intrahepatic cholangiocarcinoma, conversion therapy, chemotherapy, immunotherapy